EGR1 promoted anticancer effects of Scutellarin via regulating LINC00857/miR-150-5p/c-Myc in osteosarcoma

J Cell Mol Med. 2021 Sep;25(17):8479-8489. doi: 10.1111/jcmm.16809. Epub 2021 Aug 4.

Abstract

Scutellarin, an active flavone extracted from Erigeron breviscapus, is known to exhibit antitumour activity in many cancers. However, the effects of Scutellarin on osteosarcoma remain unclear. In this study, we found that Scutellarin suppressed osteosarcoma cell growth, induced cell apoptosis and inhibited tumorigenesis. Mechanistically, our data revealed that EGR1 was significantly increased under Scutellarin treatment. Increased EGR1 enhanced tumour-suppressive effects of Scutellarin on osteosarcoma cells via transcriptionally downregulating LINC00857 expression. Additionally, we found that LINC00857 acted as a competitive endogenous RNA of miR-150-5p and inhibited the activity of miR-150-5p, which resulted in c-Myc increase. Scutellarin could suppress c-Myc protein levels through decreasing LINC00857 expression in osteosarcoma. Thus, these findings demonstrate that EGR1/ LINC00857/miR-150-5p/c-Myc axis plays a key role in promoting anticancer effects of Scutellarin and Scutellarin might have potential clinical implication in osteosarcoma clinical treatment.

Keywords: EGR1; LncRNA; osteosarcoma; scutellarin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apigenin / pharmacology*
  • Carcinogenesis / drug effects
  • Cell Line, Tumor
  • Early Growth Response Protein 1 / metabolism*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Glucuronates / pharmacology*
  • Humans
  • MicroRNAs / metabolism*
  • Osteosarcoma* / drug therapy
  • Osteosarcoma* / metabolism
  • RNA, Long Noncoding / metabolism*

Substances

  • Antineoplastic Agents
  • EGR1 protein, human
  • Early Growth Response Protein 1
  • Glucuronates
  • LINC00857 lnc, human
  • MIRN150 microRNA, human
  • MicroRNAs
  • RNA, Long Noncoding
  • scutellarin
  • Apigenin